Amarin Corporation plc (AMRN)
Automate Your Wheel Strategy on AMRN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMRN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMRN
- Rev/Share 0.5181
- Book/Share 1.1458
- PB 13.7811
- Debt/Equity 0.0168
- CurrentRatio 3.5285
- ROIC -0.1963
- MktCap 6527933380.0
- FreeCF/Share -0.0747
- PFCF -211.3283
- PE -74.2426
- Debt/Assets 0.0121
- DivYield 0
- ROE -0.1721
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Are Medical Stocks Lagging Amarin (AMRN) This Year?
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year.
Read More
Best Momentum Stock to Buy for June 27th
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
GTX, LPG and AMRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 27, 2025.
Read More
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.
Read More
Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Read More
Amarin (AMRN) Now Trades Above Golden Cross: Time to Buy?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Amarin Corporation PLC (AMRN) is looking like an interesting pick, as it just reached a key level of support. AMRN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Read More
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Amarin (AMRN) and GSK (GSK) have performed compared to their sector so far this year.
Read More
Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Best Momentum Stocks to Buy for June 10th
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
AMRN, FIX and PATH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2025.
Read More
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
Read More
Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Amarin Corporation plc (NASDAQ:AMRN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Operator Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2025 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin.
Read More
Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance
Published: March 19, 2025 by: Business Wire
Sentiment: Neutral
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with certain of their affiliates, the “Concerned Shareholder Group” or “we”), who collectively own approximately 15 million shares of Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”), today issued the following open letter to the Company's Board of Directors. *** Amarin Corporation plc ATTN: Board of Directors (the “Board”) 88 Harcourt Street Dublin 2, Ireland.
Read More
Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript
Published: March 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Amarin Corporation plc (NASDAQ:AMRN ) Q4 2024 Earnings Conference Call March 12, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co. Operator Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2024 Business Update and Financial Results. I would like to turn the conference call over to Mark …
Read More
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with Very Well-Controlled Low-Density Lipoprotein Cholesterol (
Read More
About Amarin Corporation plc (AMRN)
- IPO Date 1993-04-01
- Website https://www.amarincorp.com
- Industry Biotechnology
- CEO Aaron D. Berg
- Employees 275